Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. (Q45012482)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. (English)

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

1 reference

based on heuristic

inferred from title

differentiated thyroid carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Marco Salvatore

8

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Antongiulio Faggiano

11

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Annamaria Colao

10

object named as

Annamaria Colao

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Vincenzo Marotta

1

object named as

Vincenzo Marotta

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

author name string

Valeria Ramundo

2

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Luigi Camera

3

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Michela Del Prete

4

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Rosa Fonti

5

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Raffaella Esposito

6

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Giovannella Palmieri

7

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Mario Vitale

9

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

publication date

1 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Clinical Endocrinology

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

78

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

760-767

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Thyroid cancer incidence and survival in the national cancer institute surveillance, epidemiology, and end results race/ethnicity groups

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Survival and death causes in differentiated thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Early clinical studies of novel therapies for thyroid cancers

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

BAY 43-9006 inhibition of oncogenic RET mutants

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

VEGF and the quest for tumour angiogenesis factors

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Sorafenib in metastatic thyroid cancer.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Phase II trial of sorafenib in advanced thyroid cancer

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Phase II trial of sorafenib in metastatic thyroid cancer

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Bevacizumab, bleeding, thrombosis, and warfarin

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Thrombotic events in patients with cancer receiving antiangiogenesis agents

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Mechanisms of adverse effects of anti-VEGF therapy for cancer

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Bowel perforation after radiotherapy in a patient receiving sorafenib.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Bronchial fistula associated with sunitinib in a patient previously treated with radiation therapy

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging Correlation

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12057

21 January 2018

Identifiers

10.1111/CEN.12057

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

8 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45012482&oldid=1509894340"